Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation

References

• Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 1992;7:369–71
   PubMed Web of Science ®Google Scholar
• Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006;24:105–12
   PubMed Web of Science ®Google Scholar
• Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649–71
   PubMed Web of Science ®Google Scholar
• Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:984–93
   PubMed Web of Science ®Google Scholar
• Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332–43
   PubMed Web of Science ®Google Scholar
• Russell J, Bass P, Goldberg LI, et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255–61
   PubMed Web of Science ®Google Scholar
• Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181–91
   PubMed Web of Science ®Google Scholar
• Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12:554–62
   PubMed Web of Science ®Google Scholar
• FDA/CDER. Clinical pharmacology and biopharmaceutics reviews [methyl-naltrexone]. 2008. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_ClinPharmR.pdf [last accessed 2 Feb 2012]
   Google Scholar
• Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997;61:467–75
   PubMed Web of Science ®Google Scholar
• Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA 2000;284:1383–4
   PubMed Web of Science ®Google Scholar
• Yu LF, Lu WG, Xiang P, et al. Enhancing oral bioavailability of methylnaltrexone using an emulsion formulation. Lett Drug Des Discov 2011;8:87–92
   Web of Science ®Google Scholar
• Wang Y, Xie H, Pan SL. Pharmacokinetics of laetispicine and its brain distribution in rats. Am J Chin Med 2010;38:895–907
   PubMed Web of Science ®Google Scholar
• Wang CZ, Du GJ, Zhen Z, et al. Significant dose differences in donepezil purchased from the United States and Canada. Ann Intern Med 2011;155:279–80
   PubMed Web of Science ®Google Scholar
• Warfield CA. Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials. Cancer 1998;82:2299–306
   PubMed Web of Science ®Google Scholar
• Walsh TD. Oral morphine in chronic cancer pain. Pain 1984;18:1–11
   PubMed Web of Science ®Google Scholar
• Yap Y, Pappagallo M. The epidemiology of opioid bowel dysfunction. In: Yuan CS, ed. Opioid bowel dysfuncion. New York: Haworth Medical Press; 2005:61–7
   Google Scholar
• Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand 2000;44:656–64
   PubMed Web of Science ®Google Scholar
• Mercadante S, Fulfaro F, Casuccio A. The impact of home palliative care on symptoms in advanced cancer patients. Support Care Cancer 2000;8:307–10
   PubMed Web of Science ®Google Scholar
• Osinski J, Wang A, Wu JA, et al. Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. J Chromatogr B Analyt Technol Biomed Life Sci 2002;780:251–9
   PubMed Web of Science ®Google Scholar
• Rotshteyn Y, Boyd TA, Yuan CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol 2011;7:227–35
   PubMed Web of Science ®Google Scholar
• Shah SM, Ofslager C. Lyophilized dry powder compound formulations comprising methylnaltrexone and uses thereof for preventing or treating side effects of analgesic opioids. Wahington (DC): Wyeth, LLC; 2008
   Google Scholar
• Shah SM, Diorio CR, Ehrnsperger EC, et al. Oral formulations and lipophilic salts of methylnaltrexone. Wahington (DC): Wyeth, LLC; 2011
   Google Scholar
• Fiore K. Oral relistor may ease bowel back-up from opiates. 2012. Available from: http://www.medpagetoday.com/MeetingCoverage/DDW/32947 [last accessed 8 Nov 2012]
   Google Scholar
• Kane E, Kane P. Compositions containing phosphatidylcholine and essential fatty acids. Millville (NJ): Bodybio Inc; 2007
   Google Scholar
• Johnsson M, Tiberg F, Nistor C. Lipid based controlled release formulations. Lund, Sweden: Camurus AB; 2009
   Google Scholar
• Caira MR. Sulfa drugs as model cocrystal formers. Mol Pharm 2007;4:310–16
   PubMed Web of Science ®Google Scholar
• Padrela L, de Azevedo EG, Velaga SP. Powder X-ray diffraction method for the quantification of cocrystals in the crystallization mixture. Drug Dev Ind Pharm 2012;38:923–9
   PubMed Web of Science ®Google Scholar
• Wang CZ, Kim KE, Du GJ, et al. Ultra-performance liquid chromatography and time-of-flight mass spectrometry analysis of ginsenoside metabolites in human plasma. Am J Chin Med 2011;39:1161–71
   PubMed Web of Science ®Google Scholar
• Lennernas H, Regardh CG. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm Res 1993;10:879–83
   PubMed Web of Science ®Google Scholar
• Katzung BG. Basic and clinical pharmacology. 12th ed. Norwalk: Appleton & Lange; 2011
   Google Scholar
• Sigal YJ, McDermott MI, Morris AJ. Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. Biochem J 2005;387:281–93
   PubMedGoogle Scholar
• Vudathala GK, Rogers JA. Oral bioavailability of griseofulvin from aged griseofulvin-lipid coprecipitates: in vivo studies in rats. J Pharm Sci 1992;81:1166–9
   PubMed Web of Science ®Google Scholar
• Baenziger JE, Ryan SE, Goodreid MM, et al. Lipid composition alters drug action at the nicotinic acetylcholine receptor. Mol Pharmacol 2008;73:880–90
   PubMed Web of Science ®Google Scholar
• Stremmel W, Hanemann A, Braun A, et al. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis – a review of three clinical trials. Expert Opin Investig Drugs 2010;19:1623–30
   PubMed Web of Science ®Google Scholar